ADVM - Adverum Biotechnologies, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Adverum Biotechnologies, Inc.

1035 O'Brien Drive
Suite A
Menlo Park, CA 94025
United States
650-272-6269
http://www.adverum.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees86

Key Executives

NameTitlePayExercisedYear Born
Dr. Mitchell H. FinerCo-Founder & Director57.48kN/A1959
Dr. Mehdi GasmiChief Science & Technology Officer634.14kN/A1967
Dr. Amber SalzmanConsultant442.82kN/A1962
Ms. Leone D. PattersonPres, CEO, CFO & DirectorN/AN/A1963
Ms. Katherine BockVP of Investor Relations and Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Corporate Governance

Adverum Biotechnologies, Inc.’s ISS Governance QualityScore as of October 1, 2018 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.